Cerebrolysin 60MG is a research-use-only peptide derived from conditioned media of brewing yeast cells exposed to neuronal tissues. Designed for laboratory-use context, this product is intended for academic and research investigations related to neuroprotective and cognitive function studies. Always used strictly under the guidance of qualified professionals. For research use only.
$79.95
Out of stock
Out of stock
Every serious peptide company prominently displays this. Example Research Use Only All products offered by Dakota Peptology are intended strictly for laboratory research purposes.
Every serious peptide company prominently displays this. Example Research Use Only All products offered by TruPeptides are intended strictly for laboratory research purposes.
Cerebrolysin is a standardized, lyophilized preparation derived from a neuroprotective fraction of bovine brain tissue. This research-use-only peptide solution is used in academic and pharmaceutical research to study neuroprotective mechanisms, cognitive function, and neurodegenerative disease models. The 60mg concentration offers a controlled dosage for experimental applications in neuroscience research.
Cerebrolysin has been extensively studied as a potential neuroprotective agent since its original development in the 1970s. As a brain extract peptide mixture, it contains a complex profile of bioactive compounds including peptides, amino acids, and low molecular weight neuroprotective factors. These components work synergistically to modulate cellular processes in the central nervous system. Researchers utilize Cerebrolysin in preclinical models to investigate mechanisms of injury repair, synaptic plasticity, and neuroinflammation.
Cerebrolysin has been evaluated in multiple research contexts including:
Its use in research represents an important tool for studying neuroprotective pathways and potential therapeutic interventions at the molecular level. The specific 60mg concentration used in these studies provides a defined experimental dose for reproducible research applications.
Cerebrolysin’s research applications are limited to academic and pharmaceutical research settings only. It is not intended for any therapeutic, diagnostic, or cosmetic purposes.
This product is intended solely for research purposes and should be handled with proper biosafety precautions. Research institutions must ensure compliance with all applicable regulations governing research materials. Researchers should conduct all experiments in accordance with institutional guidelines and ethical standards.
For research use only. Not for human or animal consumption.
Cerebrolysin is a peptide-based compound composed of low-molecular-weight peptides and amino acids derived from porcine brain tissue.
It has been studied for its potential neuroprotective and neurotrophic effects, particularly in neurological conditions such as stroke and brain injury.
The referenced study aimed to assess the benefits and risks of Cerebrolysin in patients with acute ischemic stroke.
Researchers evaluated whether treatment could improve survival, reduce complications, and enhance neurological recovery.
This study is a Cochrane systematic review of randomized controlled trials involving Cerebrolysin treatment initiated within 48 hours of stroke onset.
A total of seven clinical trials involving over 1,700 participants were analyzed, comparing Cerebrolysin with placebo or standard care.
The analysis found that Cerebrolysin likely has little to no effect on reducing all-cause mortality in acute ischemic stroke.
Additionally, there was no clear improvement in major clinical outcomes, and some data suggested an increase in non-fatal adverse events in treated groups.
Cerebrolysin is believed to act through neurotrophic and neuroprotective mechanisms, supporting neuronal survival and synaptic plasticity.
Its peptide components may mimic endogenous growth factors involved in brain repair and cellular signaling.
While Cerebrolysin demonstrates biological activity related to neuroprotection, current clinical evidence remains inconclusive regarding its effectiveness in stroke outcomes.
These findings highlight the need for further high-quality trials to determine its role in neurological recovery.
Cerebrolysin has been widely studied as a neuroprotective peptide mixture, but current evidence suggests limited clinical benefit in acute ischemic stroke.
Continued research is required to better understand its mechanisms and potential applications.
Rooted in the Midwest • Driven by Science
